T hrombocytopenia is a common complication in patients with chronic liver disease (CLD). Patients with CLD and severe thrombocytopenia (platelet count <50,000/mL) are at an increased risk of bleeding events related to surgical procedures and often receive platelet transfusions to reduce the risk of hemorrhagic events during and/or immediately after invasive procedures. 1, 2 However, there are a number of limitations to this approach including the short life span of transfused platelets, alloimmunization caused by the need for repeated platelet transfusions, 3, 4 the need for patient hospitalization or intensive care, 5 and the risks of hemolytic and nonhemolytic reactions, allergic reactions, acute lung injury, and infection. 5, 6 As a result, alternative treatments for thrombocytopenia are being sought.
Lusutrombopag (Shionogi & Co, Ltd, Osaka, Japan) has been approved in Japan for the improvement of CLDassociated thrombocytopenia in patients scheduled to undergo invasive procedures. 7 It is a chemically synthesized, orally active, small molecule human thrombopoietin (TPO) receptor agonist that activates the signal transduction pathway in the same fashion as endogenous TPO and induces platelet production. 7 Clinical studies of lusutrombopag for a new clinical application in patients with CLD have been primarily conducted in Japan. In a phase 2b dose-selection study in Japanese patients with CLD undergoing percutaneous radiofrequency ablation for primary hepatic cancer (JapicCTI-121944), the proportion of patients who did not require preoperative platelet transfusion was significantly greater with lusutrombopag at doses of 2, 3, or 4 mg. 8 No dose-related adverse events (AEs) were reported with lusutrombopag. The proportion of patients who did not receive platelet transfusion before the initial percutaneous liver ablation was 20% in the placebo group and ranged between 80.0% and 93.3% in the lusutrombopag groups. The number of transient thromboembolic events of the portal vein system observed was 1 each in the placebo and 2-mg groups, none in the 3-mg group, and 2 in the 4-mg group. Based on these results, a dose of 3 mg once daily for 7 days was considered the appropriate dose and was selected for further clinical development.
The primary objective of this phase 3 study of lusutrombopag (L-PLUS 1) was to demonstrate its superiority over placebo in reducing the need for platelet transfusions in thrombocytopenic patients with CLD scheduled to undergo invasive procedures. Secondary objectives included determination of the responder rate, duration of sustained platelet count increase, time course of the change in platelet count, and safety.
Methods

Study Design and Treatment
This multicenter, randomized, double-blind, parallelgroup, placebo-controlled, phase 3 study was conducted from October 2013 to May 2014 in 81 centers (Supplement 1) in Japan in compliance with the Ordinance on the Standards for the Conduct of Clinical Trials on Drugs and good clinical practice guidelines. The present study was registered at clinicaltrials.jp (JapicCTI-132323) and the study protocol (1304M0631) was approved by the Institutional Review Board of each participating center. All authors had access to the study data and reviewed and approved the final manuscript, which was prepared in accordance with the CONSORT reporting guidelines (Supplement 2).
The study consisted of 3 study periods: a screening period of up to 28 days, a treatment period of up to 7 days, and a post-treatment period of 28 days (Supplement 3). Potential patients who provided written informed consent were screened to assess eligibility. Eligible patients were randomly allocated on registration day to lusutrombopag 3 mg or placebo in a 1:1 ratio by the stochastic minimization method using 2 stratification factors: type of primary invasive procedure (liver ablation or coagulation or other invasive procedure) and platelet count at screening (<35,000/mL, 35,000/mL to <45,000/mL, or !45,000/mL).
Patients started receiving the assigned study drug once daily on day 1 of the treatment period and continued for up to 7 days. To prevent an excessive increase in platelet count, administration of the study drug was stopped on days 5, 6, or 7 if the platelet count had reached !50,000/mL and with an increase of !20,000/ mL from baseline. After the administration of the study drug, patients underwent specified post-treatment study assessments (post-treatment period). The invasive procedure was performed between days 9 and 14. Preoperative platelet transfusion was performed only when the platelet count was <50,000/mL. Any platelet transfusion was given between day 8 and the period immediately before performing the invasive procedure (ie, within 2 days before the day of the procedure). Platelet counts were assessed periodically from days 1 to 35, as described in Supplement 4. The presence of portal vein thrombosis was assessed by computed tomography or magnetic resonance imaging, and by ultrasonography. The schedule of diagnostic imaging is described in Supplement 5.
Participants
Key inclusion criteria were male or female patients !20 years of age, thrombocytopenia associated with chronic liver disease, platelet count of <50,000/mL, undergoing invasive procedures (excluding laparotomy, thoracotomy, craniotomy, open-heart surgery, organ resection, or partial organ resection) between 9 and 14 days after initiation of study treatment, Eastern Cooperative Oncology Group performance status grade 0 or 1, and agreement to use an appropriate method of contraception during the study.
Exclusion criteria included splenectomy; any other causes of thrombocytopenia; history of liver transplantation; Child-Pugh class C liver disorder, uncontrollable hepatic encephalopathy despite treatment, or uncontrollable ascites despite treatment at screening; active malignant tumor other than primary hepatic cancer; and history of portal vein thrombosis. Concomitant therapies that could influence platelet count were prohibited, except for rescue therapies and those related to the primary procedure (Supplement 6). Subsequent invasive procedures after day 8, except transcatheter arterial chemoembolization, lipiodolization with anticancer drugs, and transcatheter arterial embolization without lipiodol infusion for marking, were also excluded.
Endpoints and Assessments
The primary efficacy endpoint was the proportion of patients who did not require platelet transfusion before the primary invasive procedure. The secondary efficacy endpoints were the responder rate (defined as the proportion of patients for whom the platelet count reached !50,000/mL with an increase of !20,000/mL from baseline), the duration of sustained platelet count increase, and the time course of changes in platelet count. The duration of sustained platelet count increase was defined as the number of days during which the platelet count was maintained at !50,000/mL, !70,000/mL, and !50,000/mL with an increase of 20,000/mL from baseline. A post hoc analysis that explored factors (eg, splenic volume and endogenous TPO concentration) that could affect the efficacy of lusutrombopag treatment was performed (Supplement 7).
For safety assessments, the incidence of AEs, adverse drug reactions (ADRs), bleeding-related AEs, and thrombotic events, as well as laboratory tests, vital signs, and electrocardiogram findings, was evaluated. The reported AEs were coded using the Medical Dictionary for Regulatory Activities (version 17.0) terms. AEs reported by clinicians that met the standardized Medical Dictionary for Regulatory Activities query "hemorrhage terms (except laboratory terms)" were aggregated as bleeding-related AEs.
Statistical Analysis
Based on clinical data from a phase 2b study (JapicCTI-121944), 8 the proportion of patients who achieved the primary endpoint was assumed to be 70% with lusutrombopag and 20% with placebo. A sample size of 90 patients (45 patients per treatment group) would provide 99% power to detect the treatment difference at a 2-sided significance level of .05. The primary endpoint was analyzed using the Cochran-Mantel-Haenszel test, with the type of scheduled invasive procedure and platelet count at screening as stratification factors. The proportion of responders during the study was analyzed in a similar manner. The durations of sustained platelet count increases were compared between the lusutrombopag group without platelet transfusion and the placebo group with platelet transfusion by analysis of covariance.
What You Need to Know
Background Platelet transfusion is used to prevent hemorrhagic events in patients with thrombocytopenia undergoing invasive procedures. However, this technique has many limitations, including the short life span of transfused platelets, alloimmunization, hospitalization, and risk of immune reactions and infections. There is a need for alternative treatments for thrombocytopenia.
Findings
This phase 3 double-blind study evaluated the safety and efficacy of 3-mg, once-daily oral lusutrombopag in preventing the need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. In the placebo group, 12.5% of patients did not require preoperative platelet transfusion, whereas 79.2% of patients who received lusutrombopag avoided platelet transfusion.
Implications for patient care
Lusutrombopag was effective in achieving and maintaining target platelet counts; no significant safety concerns were identified. Lusutrombopag may be an effective substitute for platelet transfusion in patients with chronic liver disease and thrombocytopenia undergoing invasive procedures.
The primary analysis population was the full analysis set (FAS), defined as all randomized patients who received at least 1 dose of study drug and had a measurement of platelet count at baseline and at least once after initiation of study drug administration. The safety analysis population included all randomized patients who received at least 1 dose of the study drug.
A P value <.05 was considered statistically significant. All statistical analyses were performed using SAS (version 9.2 or higher; SAS Institute, Cary, NC).
Results
A total of 97 patients were randomized in the study: 49 patients in the lusutrombopag group and 48 patients in the placebo group (Supplement 8); 1 patient randomized to receive lusutrombopag never received the study drug. The FAS therefore included 96 patients (48 patients in each group), among whom 86 patients received the study drug for 7 days and the remaining 10 patients (lusutrombopag, 8; placebo, 2) who met the criteria for withdrawal (platelet count of !50,000/mL with an increase of !20,000/mL from baseline) were withdrawn from the study treatment. The safety analysis population comprised the same population as the FAS.
The demographic and baseline clinical characteristics for the FAS are shown in Table 1 . Overall the lusutrombopag and placebo arms were generally well matched. The mean age was 68.9 and 66.8 years, and the mean body weight was 59.73 kg and 63.87 kg in the lusutrombopag and placebo arms, respectively. However, there was some imbalance with regard to gender, with 43.8% and 62.5% being men in the lusutrombopag and placebo arms, respectively. Regarding medical history, overall 12.5%, 74.0%, 8.3%, and 7.3% had chronic hepatitis B, chronic hepatitis C, alcoholic liver disease, and nonalcoholic steatohepatitis, respectively. The mean platelet count was 40,900/mL and 39,900/mL at baseline in the lusutrombopag and placebo groups, respectively. The most commonly performed procedures were percutaneous radiofrequency ablation or microwave coagulation therapy (43.8% and 41.7% in lusutrombopag and placebo arms, respectively) and transcatheter arterial chemoembolization (27.1% and 22.9%, respectively) (see Supplement 9 for a complete enumeration of procedures performed during the study).
Primary Efficacy Measure
The proportion of patients who did not require preoperative platelet transfusion was 79.2% (38 of 48 patients; 95% confidence interval [CI], 65.0%-89.5%) in the lusutrombopag group and 12.5% (6 of 48 patients; 95% CI, 4.7%-25.2%) in the placebo group; this difference was statistically significant (P < .0001) (Figure 1 ).
Secondary Efficacy Measures
The proportion of patients who were considered responders was 77.1% (37 of 48 patients; 95% CI, 62.7%-88.0%) in the lusutrombopag group and 6.3% (3 of 48 patients; 95% CI, 1.3%-17.2%) in the placebo group (P < .0001 for difference) (Figure 2 ). The proportion of responders exceeded 50% on days 10-17 in the lusutrombopag group, peaking on day 14. There was no time point when the proportion of responders exceeded 50% in the placebo group. The time course of the change in median platelet count is shown in Figure 3A . In the lusutrombopag group among patients not receiving platelet transfusion, the median platelet count reached !50,000/mL after 5 days, and the maximum platelet count was reached after a mean of 13.4 days (median 14 [range, 6-28] days). The median maximum platelet count in patients without platelet transfusion was 87,000/mL (range, 59,000-145,000/mL) in the lusutrombopag group, whereas it was 52,000/mL (29,000-75,000/mL) among those receiving a platelet transfusion in the placebo group. Median change from baseline in platelet count in the previous groups are shown in Supplement 10; note that "baseline" is defined as just before administration of the study drug in the lusutrombopag group and just before platelet transfusion in the placebo group. Platelet transfusions contained a mean of 12.3 Japan units (1 Japan unit ¼ 2 Â 10 10 platelets). The duration of sustained platelet count increase is shown in Figure 3B . The number of days (adjusted mean AE SE) during which the platelet count was !50,000/mL was significantly higher in the lusutrombopag group (without platelet transfusion, 21.09 AE 0.99 days) than in the placebo group (with platelet transfusion, 6.05 AE 0.96 days) (P < .0001). Similarly, the number of days (adjusted mean AE SE) during which the platelet count was !70,000/mL was significantly higher in the lusutrombopag group (8.17 AE 0.75 days) than in the placebo group (0.56 AE 0.73 days) (P < .0001). The number of days (adjusted mean AE SE) during which the platelet count was maintained at !50,000/mL with an increase of !20,000/mL from baseline was significantly higher in the lusutrombopag group (12.39 AE 0.84 days) than in the placebo group (0.74 AE 0.81 days) (P < .0001).
Safety
No patients died or discontinued the administration of the study drug because of AEs. The overall incidence of AEs was 93.8% (45 of 48) in the lusutrombopag group and 100% (48 of 48) in the placebo group ( Table 2 ). The most frequently reported AEs (>20%) in both groups were postoperative fever, procedural pain, procedural hypertension, and increased aspartate aminotransferase. Six ADRs, which may have been related to the study drug, were reported in 4 of 48 patients (8.3%) randomized to lusutrombopag; these included nausea (2 patients) and pyrexia, headache, pain, and portal vein thrombosis (1 patient each). There was 1 ADR, a case of hypothermia, in the placebo group (2.1%). A serious AE of portal vein thrombosis was reported in 1 patient in the lusutrombopag group. This serious AE was considered to be probably related to lusutrombopag treatment, although the event possibly occurred due to influence of transcatheter arterial chemoembolization performed on day 10. Four patients in the placebo group also experienced serious AEs (urticaria, asthma, and ruptured esophageal varices in 1 patient each; and postoperative fever and pleural effusion in 1 patient), but none were considered to be related to treatment.
The incidence of bleeding-related AEs in the lusutrombopag group was numerically lower than that in the placebo group: 7 of 48 patients (14.6%) in the lusutrombopag group and 13 of 48 patients (27.1%) in the placebo group experienced bleeding-related AEs (Table 3) . No patients in the lusutrombopag group required platelet transfusion for a bleeding-related event. One patient in the placebo group required rescue therapy, which included a platelet transfusion and hemostatics (thrombin and polidocanol) for hemorrhage from esophageal varices.
One patient in each group had a thrombotic event. In the lusutrombopag group, portal vein thrombosis occurred after surgery on study day 14 and was considered severe and probably related to the study drug. The maximum platelet count in this patient was 79,000/mL, indicating no excessive increase. In the placebo group, superior mesenteric vein thrombosis was reported in 1 patient after surgery on study day 20; Figure 2 . Proportion of responders. *Defined as patients who achieved a platelet count !50,000/mL with an increase !20,000/mL from baseline.
† Cochran-Mantel-Haenszel test. CI, confidence interval; LUSU, lusutrombopag; PBO, placebo. the maximum platelet count recorded for this patient during the study was 60,000/mL. The event was considered to be moderate and not related to the study drug (Table 3) .
No clinically significant changes were noted in vital signs or electrocardiograms in either treatment group. Furthermore, portal blood flow was shown to be hepatopetal in all patients, with no clinically significant changes observed in either treatment group before or after the primary invasive procedure.
Post Hoc Analyses
The results of the post hoc analysis are described in Supplements 7,11, and 12.
Discussion
In this phase 3 study, the superiority of lusutrombopag 3 mg once daily for 7 days vs placebo was evaluated for efficacy and safety in thrombocytopenic patients with CLD scheduled to undergo invasive procedures. The patient population in this study included patients not only undergoing radiofrequency ablation for hepatic carcinoma as in the earlier phase 2b study, 8 but also other procedures of a minimal to moderately invasive nature. The present study met its primary endpoint with 79.2% of the patients in the lusutrombopag group avoiding preoperative platelet transfusion compared with 12.5% in the placebo group (P < .0001), confirming 10 platelets). Note: patients with platelet counts that increased to !50,000/mL between screening and baseline measurement were excluded from the analysis in panel B. *Increase in platelet count achieved. †Defined as patients who achieved a platelet count !50,000/mL with an increase !20,000/mL from baseline. LS, least square; PBO, placebo.
the results of the prior phase 2b study. 8 Additionally, 77.1% of lusutrombopag-treated patients were considered responders, compared with only 6.3% of placebotreated patients. The maximum platelet count was reached at a mean of 13.4 days after the first dose of lusutrombopag, with the platelet count remaining !50,000/mL for a mean of 21.09 days, not only during but also after surgery. In the placebo group, the duration (adjusted mean) during which the platelet count was !50,000/mL was only 6.05 days following platelet transfusion. Therefore, clinicians might consider followup surgery as feasible without additional need for transfusion.
In the patients with CLD in the present study, the mean endogenous TPO concentration at screening (0.964 AE 0.731 fmol/mL) was significantly higher than that seen in the healthy population included in a previous lusutrombopag phase 1 study (unpublished data; 0.469 AE 0.152 fmol/mL, P < .0001; Wilcoxon rank sum test). Their mean splenic volume at screening (572 cm 3 ) was also larger than that reported previously in a healthy Japanese population (104.0 cm 3 ). 9 Several observational studies have shown that both the endogenous TPO concentration and splenic volume are negatively correlated with the platelet count of patients with CLD. 1, 10 However, the present study showed that neither of these parameters influenced the thrombopoietic efficacy of lusutrombopag (Supplements 11 and 12) .
In thrombocytopenic patients with CLD undergoing invasive procedures, platelet infusion has been shown to have limited effectiveness and is associated with risks. [11] [12] [13] [14] In the present study, the maximum changes in platelet count were 36,000/mL at 12 days in the lusutrombopag group and 12,000/mL on the day of platelet transfusion in the placebo group (Supplement 10). In this study, 2 patients with antiplatelet antibodies achieved platelet count increase after receiving lusutrombopag. As shown in the present study, the efficacy of lusutrombopag can be expected even in patients with antiplatelet antibodies.
Lusutrombopag was well tolerated in this study, with the safety profile being the same as that seen in the placebocontrolled phase 2b study. 8 There were no study withdrawals due to AEs. The incidence of ADRs in the lusutrombopag and placebo groups was 8.3% and 2.1%, respectively. All except 1 of the ADRs were mild or moderate; the severe ADR was portal vein thrombosis in the lusutrombopag group, and this event was resolved. As is well known, patients with diseases such as cirrhosis are at increased risk of portal vein thrombosis. 15, 16 Therefore, the thrombosis-related events in the present study were not considered to represent specific risks with lusutrombopag.
One patient in each group experienced an asymptomatic portal system thromboembolic event, but neither event was associated with an excessive increase in platelet count. The incidence of thrombotic events was similar in the lusutrombopag and placebo groups (1 event in each group). Both events were identified postprocedure in protocol-specified imaging. Importantly, there was no excessive increase in platelet count to !200,000/mL, which is associated with an increased risk of thrombosis, as suggested by the Eltromobopag Evaluated for Its Ability to Overcome Thrombocytopenia and Enable Procedures (ELEVATE) study. 17 As a result, it is possible that there is no need for additional monitoring in patients treated with lusutrombopag.
No patients in the lusutrombopag group and 1 patient in the placebo group required rescue platelet transfusion for a bleeding-related event during or after surgery. Overall, there were numerically fewer bleeding-related events in the lusutrombopag group than in the placebo group, suggesting a possible clinical benefit to lusutrombopag treatment in patients with CLD undergoing planned invasive procedures.
In the ELEVATE study, 6 patients who received eltrombopag experienced portal vein thrombosis, 5 of whom had platelet counts over 200,000/mL. Importantly, the maximum platelet count observed with lusutrombopag in the present study was 145,000/mL. Also, in the ELEVATE study, image assessment was performed only in patients with symptoms thought to be associated with portal vein thrombosis; thus, the incidence of thrombotic events in the ELEVATE study may have been underestimated. Meanwhile, proactive assessment of the presence or absence of asymptomatic portal vein thrombosis after surgery in the present study revealed that the incidence of thrombosis in the portal vein system was similar in the placebo and lusutrombopag groups.
The present study has some limitations. First, the exclusion of patients with Child-Pugh class C liver disorder limited the generalizability of our results to patients with more severe disease because a previous pharmacokinetic study suggested that exposure tended to be higher in Child-Pugh class B than class A liver disease patients. Second, while this study showed that the risk of asymptomatic thrombotic events in the lusutrombopag group was not different from that in the placebo group, given that the study had only 48 patients per group, no firm conclusions can be drawn about the contribution of lusutrombopag to this rare adverse event. However, a recent meta-analysis of TPO agonists showed that the risk of thrombosis is elevated with eltrombopag only and that avatrombopag and lusutrombopag are associated with minimal risk. 18 However, a larger-scale study and postmarketing surveillance are required to better characterize the risk of thrombotic events more definitively. Third, the invasive procedures performed in the present study were of a minimal to moderately invasive nature and resulted in few bleeding-related events; therefore, the decrease in bleeding-related events with lusutrombopag treatment should be assessed in further studies with patients undergoing more invasive procedures.
In conclusion, in Japanese thrombocytopenic patients with CLD who are undergoing elective invasive procedures, lusutrombopag 3 mg once daily for up to 7 days was superior to placebo in reducing the need for platelet transfusion, and was well tolerated. Lusutrombopag could be an effective substitute for platelet transfusion in CLD patients with thrombocytopenia undergoing an invasive procedure.
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